• Explore /
  • Poster
  • / Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with <em>BRAF</em> V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).

Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).

Abstract Poster

Authors

null

Dirk Schadendorf

Department of Dermatology, University Hospital Essen, Essen, Germany

Dirk Schadendorf , Reinhard Dummer , Axel Hauschild , Mario Santinami , Victoria Atkinson , Mario Mandalà , Vanna Chiarion-Sileni , James M.G. Larkin , Marta Nyakas , Caroline Dutriaux , Andrew Mark Haydon , Laurent Mortier , Caroline Robert , Jacob Schachter , Christine-Elke Ortmann , Egbert De Jong , Eduard Gasal , Richard Kefford , John M. Kirkwood , Georgina V. Long

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT01682083

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9582)

DOI

10.1200/JCO.2019.37.15_suppl.9582

Abstract #

9582

Poster Bd #

153

Abstract Disclosures

Similar Posters

First Author: Reinhard Dummer

First Author: Dirk Schadendorf

First Author: Dirk Schadendorf

First Author: Judith M. Versluis